1

Durham, North Carolina

Trustee

Present

2

Palo Alto, California

Consultant

2/2022

3

AMYRIAD Pharma, Inc.

Los Angeles, California

Member, Advisory Team

2/2022

4

Tucson, Arizona

Member, Board of Directors (unpaid)

2/2022

5

Rochester, Minnesota

Member, Scientific Advisory Committee, Cardiovascular Research Center

2/2022

6

Cambridge, Massachusetts

Member, Nominating & Corporate Governance Committee of the Board of Directors

2/2022

7

Cambridge, Massachusetts

Member, Board of Directors

2/2022

8

Raleigh, North Carolina

Member, Board of Directors (unpaid)

2/2022

9

Columbus, Ohio

Member, Clinical Advisory Board (unpaid)

2/2022

10

Charleston, South Carolina

Member, Advisory Board, South Carolina Clinical & Translational Science Institute

2/2022

1

Centessa Pharmaceuticals, PLC

Board of Directors Fees

$15,222

2

Centessa Pharmaceuticals, PLC

Committee Fees

$1,902

3

Centessa Pharmaceuticals, PLC (CNTA)

None (or less than $1,001)

Option Exercise, Ordinary Income

$91,070

4

Cytokinetics, Inc.

Board of Directors Fees

$5,625

5

Cytokinetics, Inc.

Committee Fees

$1,875

6

Cytokinetics, Inc. (CYTK)

None (or less than $1,001)

Option Exercise, Ordinary Income

$2,455,244

7

Cytokinetics, Inc. (CYTK)

None (or less than $1,001)

Capital Gains

$5,001 - $15,000

8

Verily Life Sciences, LLC (research organization devoted to study of life sciences)

Salary & Bonus

$315,485

9

Verily Life Sciences, LLC, Employee Units (vested Verily Award Units)

None (or less than $1,001)

Capital Gains

$100,001 - $1,000,000

10

Google, LLC, 401(k) Savings Plan

1

Los Angeles, California

Pursuant to the terms of my agreement with the company, I was entitled to receive unvested stock options in the company should I participate in an advisory team meeting scheduled for December 2021. I did not receive stock options, and I did not receive payment for services. I do not hold any equity interests in the company.

6/2021

2

Cambridge, Massachusetts

Pursuant to the terms of the company's Amended and Restated Stock Option Incentive Plan, the Administrator of the company was authorized to and agreed to accelerate the vesting of my unvested stock options that vested prior to February 19, 2022. I divested my vested shares in March 2022. I forfeited my unvested options upon my resignation; those options were canceled. I do not hold any equity interests in the company.

1/2021

3

South San Francisco, California

Pursuant to the terms of the 2004 Equity Incentive Plan & 2004 Option Agreement and the Amended & Restated 2004 Equity Incentive Plan, upon my resignation from the company, I forfeited my unvested restricted stock units and my unvested stock options. I divested my shares of common stock and vested stock options in March 2022. I do not hold any equity interests in the company.

2/2018

4

Raleigh, North Carolina

I held vested stock options. I forfeited those vested stock options upon my resignation. I do not hold any equity interests in the company.

10/2017

5

South San Francisco, California

I owned unvested Verily Award Units. I also owned Verily Employee Units, representing an equity ownership interest in the company. Under the Verily Life Sciences, LLC, Value Creation Award Plan, when the Verily Award Units vested, they were settled in Employee Units. As is consistent with the terms of the Verily Life Sciences, LLC, Value Creation Award Plan and the benefit provided to other similarly situated executives, I was permitted to cash out my vested Employee Units at any time. The value of the units was regularly set by the board. I cashed out my vested Employee Units in March 2022, from which I received the most recent valuation at the time. I forfeited all unvested Verily Award Units upon my resignation from the company. I do not hold any equity interests in the company.

6/2017

6

Mountain View, California

I continue to retain the Google, LLC, 401(k) Savings Plan, a defined contribution plan. The plan sponsor has not made further contributions since my separation.

6/2017

1

Spouse's IRA

1.1

American Funds Fundamental Investors - Class F-3 (FUNFX)

$50,001 - $100,000

None (or less than $201)

1.2

American Funds Investment Co. of America - Class F-3 (FFICX)

$50,001 - $100,000

None (or less than $201)

1.3

American Funds New Perspective Fund - Class F-3 (FNPFX)

$15,001 - $50,000

None (or less than $201)

1.4

American Funds Washington Mutual Investors Fund - Class F-3 (FWMIX)

$1,001 - $15,000

None (or less than $201)

1.5

Applied Finance Explorer Fund - Institutional Class (AFDZX)

$50,001 - $100,000

None (or less than $201)

1.6

JPMorgan Strategic Income Opportunities Fund - Class I (JSOSX)

$15,001 - $50,000

None (or less than $201)

1.7

JPMorgan Ultra-Short Income ETF (JPST)

$15,001 - $50,000

None (or less than $201)

1.8

WisdomTree Floating Rate Treasury Fund (USFR)

$15,001 - $50,000

None (or less than $201)

1

U.S. bank account #1 (cash)

$250,001 - $500,000

None (or less than $201)

2

U.S. bank account #2 (cash)

$50,001 - $100,000

None (or less than $201)

3

U.S. credit union account (cash)

$15,001 - $50,000

None (or less than $201)

4

Virginia College Savings Plan (Virginia529), CollegeAmerica plan account #1

4.1

American Funds Fundamental Investors - Class 529-F-2 (FFXFX)

$1,001 - $15,000

None (or less than $201)

4.2

American Funds Investment Co. of America - Class 529-F-2 (FCIAX)

$1,001 - $15,000

None (or less than $201)

4.3

American Funds New Perspective Fund - Class 529-F-2 (FFPNX)

$1,001 - $15,000

None (or less than $201)

4.4

American Funds SMALLCAP World Fund - Class 529-F-2 (FSWFX)

$1,001 - $15,000

None (or less than $201)

5

Virginia College Savings Plan (Virginia529), CollegeAmerica plan account #2

Cash Distributions

$13,811

5.1

American Funds Fundamental Investors - Class 529-F-2 (FFXFX)

$50,001 - $100,000

None (or less than $201)

1

Centessa Pharmaceuticals, PLC (CNTA)

Purchase

03/14/2022

$100,001 - $250,000

2

Centessa Pharmaceuticals, PLC (CNTA)

Sale

03/14/2022

$100,001 - $250,000

3

Centessa Pharmaceuticals, PLC (CNTA)

Purchase

03/15/2022

$100,001 - $250,000

4

Centessa Pharmaceuticals, PLC (CNTA)

Sale

03/15/2022

$100,001 - $250,000

5

Cytokinetics, Inc. (CYTK)

Purchase

03/15/2022

$250,001 - $500,000

6

Cytokinetics, Inc. (CYTK)

Sale

03/15/2022

$1,000,001 - $5,000,000

7

Cytokinetics, Inc. (CYTK)

Purchase

03/16/2022

$500,001 - $1,000,000

8

Cytokinetics, Inc. (CYTK)

Sale

03/16/2022

$1,000,001 - $5,000,000

9

Verily Life Sciences, LLC, Employee Units (vested Verily Award Units)

Sale

03/17/2022

$1,000,001 - $5,000,000

10

Google, LLC, 401(k) Savings Plan: Vanguard Target Retirement 2015 Trust Select

Sale

$100,001 - $250,000

1

1

My spouse and I are the grantors of this family revocable trust.

1

2

I forwent compensation for my former position at Bitterroot Bio, Inc.

1

5

I forwent compensation for my former position at Mayo Foundation for Medical Education & Research.

1

12

I was employed by Duke University since 1980 when I was a clinical fellow, retiring in November 2019 and then taking an adjunct professor position. The adjunct professor position annually renewed.

1

19

As part of my duties with the company, I led the advisory board of Verily Life Sciences, LLC. I did not hold a separate position or title related to leading this advisory board, and I did not receive any additional compensation for it.

1

20

As part of my duties with the company, I led the advisory board of Verily Life Sciences, LLC. I did not hold a separate position or title related to leading this advisory board, and I did not receive any additional compensation for it.

6

6.1

Previously below reporting threshold.

6

8

This plan was established in November 2021, which was after I filed my nominee OGE Form 278e (Executive Branch Personnel Public Financial Disclosure Report) and before my confirmation to the position of Commissioner of Food & Drugs.

6

9

The sole underlying asset was below the value reporting threshold at the end of 2022. Remaining assets were gifted or transferred out to the family revocable trust account. Those gifts and transfers are not reportable transactions under Part 7.

6

10

The sole underlying asset was below the value reporting threshold at the end of 2022. Remaining assets were gifted or transferred out to the family trust account. Those gifts and transfers are not reportable transactions under Part 7.